Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities

References

• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2009;55:68–69.
   Google Scholar
• Li W, Tang J, Lee D, et al. Clinical translation of long-acting drug delivery formulations. Nat Rev Mater. 2022;2022:1–15.
   Google Scholar
• Nkanga CI, Fisch A, Rad-Malekshahi M, et al. Clinically established biodegradable long acting injectables: an industry perspective. Adv Drug Deliv Rev. 2020;167:19–46.
   PubMed Web of Science ®Google Scholar
• Stefanacci RG, Guerin S. Why medication adherence matters to patients, payers, providers - PubMed. Manag Care. 2013;22:37–39.
   PubMedGoogle Scholar
• Stollerman GH, Rusoff JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients: use of new respiratory penicillin preparation. J Am Med Assoc. 1952;150(16):1571–1575.
   PubMed Web of Science ®Google Scholar
• Stollerman GH. The use of antibiotics for the prevention of rheumatic fever. Am J Med. 1954;17(6):757–767.
   PubMed Web of Science ®Google Scholar
• Lee PI, and Li J-X. Evolution of oral controlled release dosage forms. In: Wen H, Park K, editors. Oral controlled release formulation design and drug delivery theory to practice. Wiley; 2010. p. 21–31. https://books.google.ch/books/about/Oral_Controlled_Release_Formulation_Desi.html?id=01kWYaIg77QC&printsec=frontcover&source=kp_read_button&hl=en&redir_esc=y#v=onepage&q&f=false
   Google Scholar
• Yun YH, Lee BK, Park K. Controlled drug delivery: historical perspective for the next generation. J Control Release. 2015;219:2–7.
   PubMed Web of Science ®Google Scholar
• O’Brien MN, Jiang W, Wang Y, et al. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144–158.
   PubMed Web of Science ®Google Scholar
• Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem Rev. 2012;112:2853–2888.
   PubMed Web of Science ®Google Scholar
• Schwendeman SP, Cardamone M, and Klibanov A, et al. Stability of proteins and their delivery from biodegradable polymer microspheres. Microparticulate Syst Deliv Proteins Vaccines. 2020;77:1–49.
   Google Scholar
• Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412–424.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. In: Sabaté E, editor. World Health Organization; 2003 https://apps.who.int/iris/handle/10665/42682
   Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–314.
   PubMed Web of Science ®Google Scholar
• Winkler A, Teuscher AU, Mueller B, et al. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas - PubMed. Swiss Med Wkly. 2002;132:379–385.
   PubMed Web of Science ®Google Scholar
• Glader EL, Sjölander M, Eriksson M, et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397–401.
   PubMed Web of Science ®Google Scholar
• Hichborn J, Kaganoff S, Subramanian N, et al. Improving patient adherence through data-driven insights [Internet]. 2018 [cited 2022 Mar 8]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/improving-patient-adherence-through-data-driven-insights
   Google Scholar
• Ruppar T, Ho PM, Garber L, et al. Overcoming barriers to medication adherence for chronic Diseases | public health grand rounds | CDC [Internet]. 2017 [cited 2022 Mar 8]. Available from: https://www.cdc.gov/grand-rounds/pp/2017/20170221-medication-adherence.html
   Google Scholar
• New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. | pSNet. 2009.
   Google Scholar
• National Council on Patient Information and Education. Accelerating progress in prescription medicine adherence: the adherence action agenda. Be Med Smart. 2013. https://www.bemedwise.org/wp-content/uploads/2019/11/a3_report.pdf
   Google Scholar
• Walensky RP, Jacobsen MM, Bekker LG, et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV Infection. J Infect Dis. 2016;213:1523–1531.
   PubMed Web of Science ®Google Scholar
• Gonzalez AZ, Jermain SV, and Roberts EB, et al. The drug substances of long-acting injectables: examples from Hormone, CNS, and antiviral therapies. In: Bronson JJ, editor. Vol 55, Medicinal Research Reviews; 2020. chapter 16; p. 383–407.
   Google Scholar
• Voss EA, Ryan PB, Stang PE, et al. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol. 2015;30:151.
   PubMed Web of Science ®Google Scholar
• Parker B, Ward T, Hayward O, et al. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study. PLoS One. 2021;16:e0245955.
   PubMed Web of Science ®Google Scholar
• Lyndra Inc. What if we stop trying to change the patient, and changed the pill instead? [Internet]. 2018 [cited 2022 Mar 28]. Available from: https://unitaid.org/assets/Lyndra-NC-September-2018.pdf
   Google Scholar
• Iglay K, Cao X, Mavros P, et al. Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther. 2015;37:1813–1821.e1.
   PubMed Web of Science ®Google Scholar
• PharmaCircle™ [Internet]. [cited 2022 Mar 17]. Available from: https://www.PharmaCircle™.com/
   Google Scholar
• Jin J-F, Zhu -L-L, Chen M, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923–942.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10:45.
   PubMed Web of Science ®Google Scholar
• Collins DS, Sánchez-Félix M, Badkar A V, et al. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475–482.
   PubMed Web of Science ®Google Scholar
• Meir R. Home infusion trend stirs debate. OncologyLive. 2021;22(21). https://www.onclive.com/view/home-infusion-trend-stirs-debate
   Google Scholar
• PharmaPendium [Internet]. [cited 2022 Mar 17]. Available from: https://www.pharmapendium.com/
   Google Scholar
• Powering healthcare with connected intelligence - IQVIA [Internet]. [cited 2022 Apr 7]. Available from: https://www.iqvia.com/
   Google Scholar
• Van ’t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54:2042–2050.
   PubMed Web of Science ®Google Scholar
• Butreddy A, Gaddam RP, Kommineni N, et al. PLGA/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein/peptide delivery. Int J Mol Sci. 2021;22:8884.
   PubMed Web of Science ®Google Scholar
• FDA. ELIGARD® 7.5 mg, 22.5 mg, 30 mg, 45 mg (leuprolide acetate for injectable suspension).
   Google Scholar
• Campbell IB, Macdonald SJF, Procopiou PA. Medicinal chemistry in drug discovery in big pharma: past, present and future. Drug Discov Today. 2018;23:219–234.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Kuntz ID, Chen K, Sharp KA, et al. The maximal affinity of ligands. Proc Natl Acad Sci U S A. 1999;96:9997–10002.
   PubMed Web of Science ®Google Scholar
• Hann MM. Molecular obesity, potency and other addictions in drug discovery. Medchemcomm. 2011;2:349–355.
   Web of Science ®Google Scholar
• Aungst BJ. Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options. J Pharm Sci. 2017;106:921–929.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008;364:213–226.
   PubMed Web of Science ®Google Scholar
• Prinderre P, Sauzet C, Fuxen C. Advances in gastro retentive drug-delivery systems. Expert Opin Drug Deliv. 2011;8:1189–1203.
   PubMed Web of Science ®Google Scholar
• Altreuter DH, Kirtane AR, Grant T, et al. Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form. Expert Opin Drug Deliv. 2018;15:1189–1198.
   PubMed Web of Science ®Google Scholar
• Lyndra therapeutics announces positive outcome of end-of-phase 2 Meeting with the FDA for Lyndra’s weekly risperidone (LYN-005) for the treatment of adults with schizophrenia and other indications | business Wire [Internet]. [cited 2022 Mar 1]. Available from: https://www.businesswire.com/news/home/20210719005181/en/Lyndra-Therapeutics-Announces-Positive-Outcome-of-End-of-Phase-2-Meeting-with-the-FDA-for-Lyndra’s-Weekly-Risperidone-LYN-005-for-the-Treatment-of-Adults-with-Schizophrenia-and-Other-Indications
   Google Scholar
• Lyndra therapeutics presents preclinical data on once-weekly oral buprenorphine treatment, LYN-013, in development for opioid use disorder | business wire [Internet]. [cited 2022 Mar 1]. Available from: https://www.businesswire.com/news/home/20210625005069/en/Lyndra-Therapeutics-Presents-Preclinical-Data-on-Once-Weekly-Oral-Buprenorphine-Treatment-LYN-013-in-Development-for-Opioid-Use-Disorder.
   Google Scholar
• Varum FJO, Merchant HA, Basit AW. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption. Int J Pharm. 2010;395:26–36.
   PubMed Web of Science ®Google Scholar
• Kovačič NN, Pišlar M, Ilić I, et al. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles. Int J Pharm. 2014;473:552–559.
   PubMedGoogle Scholar
• Bellinger AM, Jafari M, and Grant TM, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2017;8(365)365ra157. DOI:10.1126/scitranslmed.aag2374.
   Web of Science ®Google Scholar
• Kanasty R, Bellinger A, Gardner C, et al. WO 2017/070612 A1 Gastric residence systems for sustained release of therapeutic agents and methods of use thereof. 2017.
   Google Scholar
• Chamanza R, Darville N, van Heerden M, et al. Comparison of the local tolerability to 5 long-acting drug nanosuspensions with different stabilizing excipients, following a single intramuscular administration in the rat. Toxicol Pathol. 2018;46:85–100.
   PubMed Web of Science ®Google Scholar
• Bao Q, Zou Y, Wang Y, et al. Impact of formulation parameters on in vitro release from long-acting injectable suspensions. AAPS J. 2021;23:1–11.
   Web of Science ®Google Scholar
• Pons-Faudoa FP, Ballerini A, Sakamoto J, et al. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices. 2019;21:1–22.
   Web of Science ®Google Scholar
• Krovi SA, Johnson LM, Luecke E, et al. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention. Adv Drug Deliv Rev. 2021;176:113849.
   PubMed Web of Science ®Google Scholar
• Samumed L. PROTOCOL SM04690-OA-04 [Internet]. 2018 [cited 2022 Feb 28]. Available from: https://www.clinicaltrials.gov/ProvidedDocs/60/NCT03122860/Prot_000.pdf
   Google Scholar
• Shatz W, Aaronson J, Yohe S, et al. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases. Expert Opin Drug Deliv. 2019;16:43–57.
   PubMed Web of Science ®Google Scholar
• Patel SR, Lerner SP. Novel thermo-sensitive hydrogel therapy for low-grade upper tract urothelial carcinoma. J Urol. 2021;206:191–193.
   PubMed Web of Science ®Google Scholar
• Fung A. A novel sustained- release intravitreal drug delivery system for retinal vascular disease. Cover story. 2010;51–53.
   Google Scholar
• Ma Z, Zhang H, Wang Y, et al. Development and evaluation of intramuscularly administered nano/microcrystal suspension. Expert Opin Drug Deliv. 2019;16:347–361.
   PubMed Web of Science ®Google Scholar
• Darville N, Van Heerden M, Vynckier A, et al. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. J Pharm Sci. 2014;103:2072–2087.
   PubMed Web of Science ®Google Scholar
• Darville N, Van Heerden M, Erkens T, et al. Modeling the time course of the tissue responses to intramuscular long-acting paliperidone palmitate nano-/microcrystals and polystyrene microspheres in the rat. Toxicol Pathol. 2016;44:189–210.
   PubMed Web of Science ®Google Scholar
• Fagerberg JH, Tsinman O, Sun N, et al. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm. 2010;7:1419–1430.
   PubMed Web of Science ®Google Scholar
• Wassvik CM, Holmén AG, Draheim R, et al. Molecular characteristics for solid-state limited solubility. J Med Chem. 2008;51:3035–3039.
   PubMed Web of Science ®Google Scholar
• Bergström CAS, Wassvik CM, Johansson K, et al. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 2007;50:5858–5862.
   PubMed Web of Science ®Google Scholar
• Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–1020.
   PubMed Web of Science ®Google Scholar
• Deshmukh V, Hu H, Barroga C, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2018;26:18–27.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research. Application number: 207946Orig1s000 Chemistry review(s) NDA 207946 Invega Trinza [Internet]. 2015 [cited 2022 Feb 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207946Orig1s000ChemR.pdf
   Google Scholar
• FDA. Highlights of prescribing information Invega Hafyera [Internet]. 2021 [cited 2022 Feb 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946s010lbl.pdf.
   Google Scholar
• Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396(10267):1994–2005.
   PubMed Web of Science ®Google Scholar
• Begley R, Lutz J, Rhee M, et al. Lenacapavir sustained delivery formulation supports 6-month dosing interval [Internet]. Present. AIDS 2020 23rd Int. AIDS Conf. Virtual, 6-10 July 2020. [cited 2022 Mar 14]. Available from: https://www.hivandmore.de/kongresse/iac2020/Begley_LEN-Sustained-delivery-formulation-supports-q6mo-dosing_AIDS2020_PEB0265_Submitted.pdf.
   Google Scholar
• Gilead Sciences Inc. CLINICAL STUDY PROTOCOL study title: a Phase 2/3 study to evaluate the safety and efficacy of long acting capsid inhibitor GS-6207 in combination with an optimized background regimen in heavily treatment experienced people living with HIV-1 infection with multidrug resistance [Internet]. 2020 [cited 2022 Mar 25]. Available from: https://clinicaltrials.gov/ProvidedDocs/68/NCT04150068/Prot_000.pdf
   Google Scholar
• Bodick N, Blanks R C, Kumar A, et al. United States Patent USO09555047B2. 2017.
   Google Scholar
• Kraus VB, Conaghan PG, Aazami HA, et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthr Cartil. 2018;26:34–42.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research. Application number: 208845Orig1s000 Clinical pharmacology and biopharmaceutics review(s). 2016.
   Google Scholar
• Johnson AR, Forster SP, White D, et al. Drug eluting implants in pharmaceutical development and clinical practice. Expert Opin Drug Deliv. 2021;18:577–593.
   PubMed Web of Science ®Google Scholar
• Santarelli GD, Han JK. Evaluation of the PROPEL ® mini sinus implant for the treatment of frontal sinus disease. Expert Opin Drug Deliv. 2016;13:1789–1793.
   PubMed Web of Science ®Google Scholar
• ozurdex.com [Internet]. [cited 2022 Feb 25]. Available from: https://www.ozurdex.com/
   Google Scholar
• Thakur RRS, McMillan HL, Jones DS. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J Control Release. 2014;176:8–23.
   PubMed Web of Science ®Google Scholar
• Tiberg F, Harwigsson I, Johnsson M. US20130190341A1 - High bioavailability opioid formulations. 2005.
   Google Scholar
• Kado JH, Salman S, Henderson R, et al. Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers. J Antimicrob Chemother. 2020;75:2951–2959.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Byannli International non-proprietary name: paliperidone [Internet]. 2021 [cited 2022 Mar 24]. Available from: https://www.ema.europa.eu/en/documents/variation-report/byannli-h-c-5486-x-02-g-epar-assessment-report-variation_en.pdf
   Google Scholar
• Kulkarni TA, Bade AN, Sillman B, et al. A year-long extended release nanoformulated cabotegravir prodrug. Nat Mater. 2020;19:910–920.
   PubMed Web of Science ®Google Scholar
• Hilaire JR, Bade AN, Sillman B, et al. Creation of a long-acting rilpivirine prodrug nanoformulation. J Control Release. 2019;311–312:201–211.
   PubMed Web of Science ®Google Scholar
• Hines M, Lyseng-Williamson KA, Deeks ED. 17 a-hydroxyprogesterone caproate (Makena) A guide to its use in the prevention of preterm birth. Clin Drug Investig. 2013;33:223–227.
   PubMed Web of Science ®Google Scholar
• PharmaCircle™ Short Report. Injectables – long acting by design. Approved Product Overview, 1960s to 2019. 2019.
   Google Scholar
• Rudd ND, Reibarkh M, Fang R, et al. Interpreting in vitro release performance from long-acting parenteral nanosuspensions using USP-4 dissolution and spectroscopic techniques. Mol Pharm. 2020;17:1734–1747.
   PubMedGoogle Scholar
• Hammarlund-Udenaes M. Microdialysis as an important technique in systems pharmacology-a historical and methodological review. AAPS J. 2017;19:1294–1303.
   PubMed Web of Science ®Google Scholar
• Elmquist WF, Sawchuk RJ. Use of microdialysis in drug delivery studies. Adv Drug Deliv Rev. 2000;45:123–124.
   PubMed Web of Science ®Google Scholar
• De Lange ECM, De Boer AG, Breimer DD. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev. 2000;45:125–148.
   PubMed Web of Science ®Google Scholar
• Yáñez JA, Remsberg CM, Sayre CL, et al. Flip-flop pharmacokinetics - Delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2:643–672.
   PubMedGoogle Scholar
• Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2009;33:1022–1031.
   PubMed Web of Science ®Google Scholar
• Darville N, Van Heerden M, Mariën D, et al. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J Control Release. 2016;230:95–108.
   PubMed Web of Science ®Google Scholar
• Gao J, Xia Z, Mary HB, et al. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs. Trends Pharmacol Sci. 2022;43:171–187.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and drug administration, Center for Drug Evaluation and Research (CDER). Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [Internet]. 2005 [cited 2022 Mar 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers
   Google Scholar
• Bussing D, Shah D K. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits. J Pharmacokinet Pharmacodyn. 2020;47:597–612.
   PubMed Web of Science ®Google Scholar
• Le Merdy M, Mullin J, Lukacova V. Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study. J Pharmacokinet Pharmacody. 2021;48:909–922.
   PubMed Web of Science ®Google Scholar
• Kublin JG, Murphy SC, Maenza J, et al. safety, pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum Human Infection Study. Clin Infect Dis. 2021;73:2407–2421.
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT. Elsulfavirine: first global approval. Drugs. 2017;77:1811–1816.
   PubMed Web of Science ®Google Scholar
• Yu M, Benjamin MM, Srinivasan S, et al. Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018;130:113–130.
   PubMed Web of Science ®Google Scholar
• Yang W, Gadgil P, Krishnamurthy VR, et al. The evolving druggability and developability space: chemically modified new modalities and emerging small molecules. AAPS J. 2020;22:22.
   PubMed Web of Science ®Google Scholar